L-ORNITHINE L-ASPARTATE [LOLA] IMPROVES BOTH SEVERE ENCEPHALOPATHY AND SURVIVAL IN PATIENTS WITH LIVER CIRRHOSIS: RESULTS OF RCTS, SYSTEMATIC REVIEWS AND META-ANALYSES

ISHEN 20.23



INTRODUCTION

- Liver Cirrhosis remains a leading cause of death in 2023.
- Variations in age-standardized death rates according to geographic location and etiology of cirrhosis^[1]
- LOLA: improves encephalopathy grade and survival in many studies^[2]

AIMS

Systematic review of evidence from RCTs of improved HE and survival by LOLA


METHODS

- Electronic/manual searches of data from published RCTs
- Use of Random Effects Model [Pooled Risk Ratio, RR] with 95 % CI

- LOLA [p<0.005]
- LOLA [p<0.022]
- iv LOLA
- by oral LOLA
- oral LOLA

- to 0.72
- Jain et al., 2021: Hepatology, DOI:10.1002/hep.3225.
- with rifaximin + lactulose

Consort Diagram [design, randomization, outcomes]



Roger F Butterworth PhD DSc FRCP, Professor [Ret.] Department of Medicine [University of Montreal] Montreal, Canada

RESULTS

LOLA reduced mortality by > 50 % in majority of published RCTs

Intravenous and oral formulations of LOLA equally effective^[3] - Kircheis et al., 1997: No significant effects of iv LOLA on mortality - Stauch et al., 1998: No significant effects of oral LOLA on mortality - Chen et al., 2005: Decreased mortality from 7/40 in control by iv

- Ahmad et al., 2008: Decreased mortality from 4/40 in control by iv

- Abid et al., 2011: Decreased mortality from 7/60 in control to 4/60 by

- Mittal et al., 2011: No significand effects of oral LOLA on mortality - Sharma et al., 2016: Decreased mortality from 2/30 in control to 0/31

- Varakanahalli et al., 2017: Decreased mortality from 10/72 to 5/73 by


- Sidhu et al., 2018: Decreased mortality from 6/95 to 1/98 by oral LOLA

Follow-up meta-analysis by Cochrane Database Procedure^[4] - significant reduction of all-cause mortality with RR:0.42, 95 % CI:0.24

LOLA/lactulose/rifaximin combined more effective than lactulose/ rifaximin alone for improvement of OHE and 28-day mortality rates^[5]

- 140 patients randomized to receive LOLA or placebo in combination

- Outcome measures: improvement in OHE by day 5, mortality at 28 days




LOLA group (n = 70)


LOLA 30 g (6 x 5 g)/d IV over 24 hours for 5 days (+) Standard treatment: - Lactulose syrup 30-120 ml 3x/d **or** 300 ml in 700 ml H2O 2x/d nasogastric/oral


– Rifaximin 550 mg 2x/d nasogastric

Protective effects of LOLA: Possible mechanisms involving LOLA-indiced reductions of ammonia and proinflammatory markers



- 1]. Significantly greater reductions of blood ammonia in LOLA-treatment group compared to placebo.
- 2]. Selective reductions of proinflammatory markers [TNF-alpha, IL-6] in LOLA Treatment group compared to placebo.
- 3]. Improved 28-day survival in patients treated with LOLA compared to placebo [Kaplan Meier analysis]





>>> Combination therapy with LOLA resulted in significantly higher survival rates.*

At 28 days of follow-up, 11 of 67 patients (16.4%) —— in the LOLA arm died, compared to 28 of 67 patients (41.8%) in the placebo arm (p = 0.001).

- compared to placebo
- [3] Findings confirmed by meta-analyses
- lity^[4]
- monemia

REFERENCES & CONTACT

- 20, 388-398
- /s/11011-019-00463-8.

Roger F Butterworth PhD DSc FRCP Professor, Dept of Medicine, University of Montreal rb@enceph.com

> or download at www.ishen.org/media/library-2023

CENTRE DE RECHERCHE

CONCLUSIONS

[1] Pooled data from 9 RCTs confirmed significant beneficial effects of LOLA on OHE grades with improvements in survival rates in 6 trials

[2] Intravenous and oral formulations of LOLA equally effective

[4] Combination therapy [LOLA, lactulose, rifaximin] superior to lactulose/rifaximin alone for treatment of OHE grades and 28-day morta-

[5] Beneficial effects of LOLA in combination therapy trial accompanied by greater reductions of hyperammonemia and selective reduced levels of pro-inflammatory markers

[6] Beneficial effects on HE and survival in cirrhosis likely result from bimodal actions of LOLA on systemic inflammation and hyperam-

(1) Huang DQ et al., 2023, Nature Reviews Gastroenterology & Hepatology,

(2) Butterworth RF, 2019, Metabolic Brain Dis., doi:10.1007

(3) Butterworth RF, McPhail MJW, 2019, Drugs 79 (Suppl.1), 3[3]

(4) Goh ET, et al., Cochrane Database Syst Rev.,2018, 5(5): CD12410.

[5] Jain A, et al., Hepatology, 2021, 00(1-10), doi.org/10.1002/hep.32255.

LINK ISHEN

Scan here

